A
Alcista
Alcista · 25%DXCM
$107.62
Precio del escenario
$86.040
-1.635 (-1.90%)Al cierre
Loading chart…
- Máximo
- 88.870
- Apertura
- 87.925
- Precio medio ponderado por volumen
- 86.90
- Volumen
- 3.59M
- Capitalización
- 45.55B
- Mínimo
- 85.800
- Importe
- 311.56M
- EV/EBITDA, TTM
- 19.58
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.
Análisis de IA of Dexcom Inc (DXCM)
ComprarDexcom Inc (DXCM) is a good buy right now, trading at $86.04 with a forward P/E of 28.25, indicating potential for growth. The company's gross margin stands at 63.44%, reflecting strong profitability. Analyst targets suggest a potential upside, with BTIG raising their target to $96 and Barclays initiating at $115. The main risk is the recent 20-day change of -3.70%, indicating some volatility, but the overall long-term outlook remains positive.
Recomendaciones de analistas (18)
-4.07% Potencial de caída
Comprar
11 Comprar
7 Mantener
0 Vender
Actual: 86.04
Mínimo
68.00
Promedio
82.54
Máximo
100.00
BTIG
Comprar
$96
2026-10-12
BTIG
2026-10-12
Precio objetivo
$96
Comprar
Barclays
Sobreponderar
$115
2026-10-06
Barclays
2026-10-06
Precio objetivo
$115
Sobreponderar
RBC Capital
Superar al mercado
$105
2026-10-01
RBC Capital
2026-10-01
Precio objetivo
$105
Superar al mercado
Citi
Comprar
$105
2026-08-13
Citi
2026-08-13
Precio objetivo
$105
Comprar
Argus
Comprar
$96
2026-08-04
Argus
2026-08-04
Precio objetivo
$96
Comprar
Métricas de valoración
El PER previsto actual de Dexcom Inc (DXCM) es 28.25, frente a su media de 5 años de 68.76.
Escenarios de precio de Alphio AI para DXCM
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con DXCM en cartera
Cronología de eventos
Noticias
9.010-14NewsfilterDexcom G7 Breakthrough in Diabetes Management
9.510-07NewsfilterDexCom Announces Q3 2026 Financial Results Release Plan
8.510-06NewsfilterDexcom Launches First NIL Program for Diabetic Athletes
2.009-28NASDAQ.COMDexcom Releases 2026 State of Type 2 Diabetes Report Highlighting Key Challenges
- 8.509-28Newsfilter
Dexcom Releases State of Type 2 Diabetes Report Highlighting Key Challenges
Preguntas frecuentes sobre DXCM, respondidas por Alphio AI
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Dexcom Inc (DXCM) is a good buy right now, trading at $86.04 with a forward P/E of 28.25, indicating potential for growth. The company's gross margin stands at 63.44%, reflecting strong profitability. Analyst targets suggest a potential upside, with BTIG raising their target to $96 and Barclays initiating at $115. The main risk is the recent 20-day change of -3.70%, indicating some volatility, but the overall long-term outlook remains positive.
18 analysts cover DXCM: 11 rate it Buy, 7 Hold and 0 Sell. The average price target is 82.54.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.